U.S.S.N. 10/012,202 Filed: December 5, 2001

AMENDMENT UNDER 37 C.F.R. 1.312

## Amendment

## In the Specification

Please replace the paragraph on page 10, lines 9-25 with the following paragraph.

Agents such as analgesics, anti-tussive agents, expectorants, anti-inflammatory agents, anti-pyretic agents, and decongestants can also be included. These agents allow control of symptoms which are common among patients who suffer from allergic rhinitis, common cold, flu, and various other allergic reactions. These agents may be in immediate release form or preferably are in sustained release form. The sustained release is achieved by formulating the particular agent with a sustained-release control polymer selected from the group consisting of methyl cellulose, ethyl cellulose, wax, gums, cellulose acetate, cellulose acetate phthalate, hydroxypropylmethylcellulose acetate-succinate phthalate, polyvinyl acetate phthalate, acrylic acid polymers and copolymers, polymers or copolymers of methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate, ethyl methacrylate, hydroxypropyl methyl cellulose acetate succinate, shellac, cellulose acetate trimellitate, vinyl acetate and combinations thereof.

Please replace the paragraph on page 24, lines 1-3 with the following paragraph.

Preparation of a granulation containing dexbrompheniramine maleate, pseudoephedrine sulfate, and loratadine cetirizine enteric coated beads.

Please replace the table on page 24, lines 4-14 with the following table.

2

45048929

U.S.S.N. 10/012,202 Filed: December 5, 2001

AMENDMENT UNDER 37 C.F.R. 1.312

INGREDIENTS	%/DOSAGE UNIT (RANGE)	mg/DOSAGE UNIT (A TYPICAL FORMULATION)
Dexbrompheniramine maleate	5 - 4	3
Pseudoephedrine sulfate	0 - 20	30
Lactose	40 - 80	145
Pregelatized Starch 1500	5 - 20	25
Microcrystalline cellulose	10 - 30	45
Magnesium stearate	2 - 1	1.1
Purified water	qs	(To be evaporated)
Loratadine Cetirizine	5 - 20	17
enteric coated		
beads		
Total		266.1

Please replace the paragraph on page 28, lines 1-9 with the following paragraph.

Each finished double-layer tablet contains the following active ingredients:

- (1) The first layer contains:
  - (a) 3 mg dexbrompheniramine maleate and 30 mg pseudoephedrine sulfate for immediately immediate release.
  - (b) 7 mg loratadine cetirizine which is enteric coated for delayed release 4-8 hours after administration.
- (2) The second layer contains 210 mg pseudoephedrine sulfate for sustained release over 24 hours.

45048829

3

CP 103 085337.6